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Abstract The aim of this study was to assess the
prevalence of congenital heart defects (CHDs) and persis-
tent pulmonary hypertension of the neonate (PPHN) in
children with Down syndrome (DS) and to assess its impact
on neonatal factors. It was a prospective study of a birth
cohort of children with DS born between 2003 and 2006
registered by the Dutch Paediatric Surveillance Unit
(DPSU). A CHD occurred in 43% of 482 children with
trisomy 21. Atrioventricular septal defect was found in
54%, ventricular septal defect in 33.3% and patent ductus
arteriosus in 5.8%. The incidence of PPHN in DS was
5.2%, which is significantly higher than the general
population (p<0.001). The reported mortality in newborns
with DS was overall 3.3% and was still significant higher in
children with a CHD versus no CHD (5.8% versus 1.5%)
(p=0.008). The presence of CHD in children with DS had
no influence on their birth weight, mean gestational age and
Apgar score. In neonates with DS, we found not only a
43% prevalence of CHD, but also a high incidence of
PPHN at 5.2%. Early recognition of the cardiac condition
of neonates with DS seems justified.
Keywords Down syndrome . Prevalence . Persistent
pulmonary hypertension of the neonate . Congenital heart
defects . Neonate
Introduction
Down syndrome (DS) is the most common autosomal
chromosome anomaly, affecting 16 out of every 10,000 live
births in the Netherlands [19]. DS is frequently associated
with congenital heart defects (CHD). Indeed CHDs are
considered to be the most important clinical phenomenon of
DS highly relevant to morbidity and decisive in infant
mortality [16]. Over recent decades, there has been a
substantial increase in the life expectancy of children with
DS in general with an improvement in average life
expectancy from 12 years in the 1940s to 60 years
nowadays [16]. This increase in life expectancyhas mainly
been due to the successful early surgical treatment of CHD
in children with DS [5, 9, 10, 16].
Atrio-ventricular septal defect (AVSD), ventricular septal
defect (VSD) and atrial septal defect (ASD) are the most
common forms of CHD and recent reports have shown that
the distribution of CHDs in children with DS may vary with
ethnicity [3, 4, 7, 8, 14, 15, 17, 20].
In addition, Shah et al. have recently identified
persistent pulmonary hypertension of the neonate (PPHN)
in 24 out of 175 children with DS retrospectively; this
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increased prevalence in children with DS has not previously
been identified as a specific problem among children with
DS [13].
In the present study, we describe the prevalence of
CHDs in neonates with DS in the Netherlands, determine
the incidence of PPHN in this population and analyse the
effect of a CHD on other neonatal factors.
Patients and methods
Our study includes all live births of children born between
January 1, 2003 and December 31, 2006 who were
diagnosed with DS and were reported to the Dutch
Paediatric Surveillance Unit (DPSU). The DPSU is a
national registry used by paediatricians to report various
paediatric disorders, including DS. For each DS case
reported to the DPSU, a questionnaire was sent to the
attending pediatrician. The completed forms were returned
to the Down Syndrome Study Group at the VU University
Medical Center, Amsterdam. The method and details of
the data collection have already been described earlier,
and in 2003 the response rate for the DPSU was 96% and
the overall response rate between 2003 and 2006 was
93.3% [19].
The diagnosis of DS was made in 91% in the first 7 days
of life in the Netherlands, and most questionnaires were
returned within the first 3 months after birth. In the
Netherlands, 20% of the population under the age of 18 is
from an ethnic minority background [19].
Only children with a karyotype analysis (antenatal or
postnatal) were included. To ensure the homogeneity of
the children with DS, all children with DS due to
mosaicism or translocation were excluded. Children with
DS for whom information regarding their cardiac status
was absent or incomplete were also excluded. The Dutch
DS screening program carries out an echocardiogram
within the first 3 months of birth. We used the following
items in the questionnaire for the analyses: sex, chromo-
somal analysis, ethnicity, cardiac evaluation, birth weight,
gestational age of birth, 5-min Apgar score and the
presence of PPHN. The diagnosis of PPHN was based
on a clinical assessment and echocardiogram in the first
week of life performed by neonatologists or paediatric
cardiologists who answered the questionnaires. PPHN is
defined, if the pulmonary pressure exceeds the systemic
pressure, as being present a right-to-left shunt and is
diagnosed by echocardiography. The use of a high
percentage of oxygen is needed usually without a reaction
on 100% oxygen and a difference in oxygen saturation
measured pre-ductal and post-ductal, when a PDA is
present [1, 13, 18]. Secundum ASD and persistent foramen
ovale (PFO) were excluded as a CHD.
Statistical analysis
The binomial test was used to compare the prevalence of
CHD and PPHN in children with DS and the Dutch
reference population, respectively. We tabulated the fre-
quency of CHD and the combinations of CHDs. Statistical
comparisons of birth weight and gestational age for
children with DS with and without CHD were made with
independent sample t tests. Because of the influence of the
gestational age on birth weight, we corrected birth weight
for gestational age by using a multiple regression model.
We used the Mann–Whitney test to compare non-
parametric variables (e.g. Apgar score) and the Chi-square
test for paired comparison of properties (e.g. asphyxia,
ethnicity and mortality). Statistical analysis was performed
with SPSS 16.0 statistical software. A p value of <0.05 was
considered significant.
Results
Study group
The DPSU registered 820 children with DS who were born
between January 1, 2003 and December 31, 2006. A total
of 630 questionnaires were returned by the DPSU, and of
these, 482 included complete data regarding the cardiac
status. A CHD was reported in 207 (43%) of the children
with trisomy 21, which is significantly higher than the
prevalence of CHD in the Dutch reference population
(0.62%, p<0.001) [12] (Fig. 1).
In 2003, the prevalence in the Netherlands of live and
still-born children with DS was 26.8 per 10,000 pregnan-
cies compared with 16 newborns with DS per 10,000 live
births; there were no exact data on the prevalence of CHD
in these stillborn children with DS [19].
Congenital heart defects
The data for CHD in children with DS are summarized in
Table 1. In 2.4% (n=5) of children, the CHD did not match
any of the categories mentioned and thus these were thus
counted as ‘other’. In 28.9% (n=60) of the children, there
were multiple cardiac defects (i.e. a combination of
defects).
Ethnicity
The ethnic background of children with DS was reported
for 404 children and was predominantly Caucasian (77.5%,
n=313). Of these Caucasian children, 127 (40.6%) had a
CHD. In 22.5% (n=91), one or both of the parents came
from an ethnic minority group most of which were from a
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Moroccan, Turkish or Antillean background. Within this
ethnic group, 42.9% (n=39) of the children with DS had a
CHD. There were no differences in the distribution of
CHDs neither in the ethnic group compared to the
Caucasian group nor within the ethnic subgroups. The data
on ethnicity were missing for 78 children with DS.
Persistent pulmonary hypertension of the neonate
PPHN was reported in 25 children with DS; an incidence
of 5.2%, which is significant, elevated in comparison with
the reported 0.1% in the general population (p<0.001)
[18]. Table 2 shows the distribution of CHDs in children
with DS and PPHN of which 36% (n=9) of the children
had no CHD.
Neonatal variables
The presence or absence of a CHD had no significant
relationship with birth weight and gestational age. The
mean birth weights of the children with and without a CHD
were 2,926 and 3,013 g, respectively (95% CI; −270–87),
and the mean gestational age of the children with DS
with and without CHD were 38.0 and 38.3 weeks,
respectively (95% CI; −0.64–0.16). The median of the
Apgar score at 5 min was nine in children with DS both
with and without a CHD. Also, the frequency of asphyxia
(Apgar score <6) in children with DS with a CHD did
not differ from those without a CHD (1.6% versus 2.8%)
(p=0.39).
Mortality
The reported mortality among the neonates with DS was16
out of 482 (3.3%). Most of the 16 children with DS died
within 30 days of birth (n=11), one died on day 39 and
Table 1 Children with Down syndrome and a congenital heart defect
(CHD; total n=207)
Congenital heart defect (CHD) N Percent
Single defect 147 71.0
AVSD 92 44.4
VSD 38 18.4
PDA 12 5.8
Other
Hypoplastic pulmonary arteries 1 0.5
COA 1 0.5
PS 2 1.0
AR 1 0.5
Combination of defects 60 29.0
AVSD + TOF 3 1.5
AVSD + ASD 6 2.9
AVSD + other
Hypoplastic aortic arch 1 0.5
IAA-b 1 0.5
PS 1 0.5
TOF 8 3.9
VSD + ASD 29 14.0
VSD + overriding AO 2 1.0
ASD + PS 7 3.4
Other
CAT-II + IAA-a 1 0.5
DAA 1 0.5
Total 207 100.0
ASD secundum atrial septal defect, AVSD atrioventricular septal
defect, VSD ventricular septal defect, PDA patent ductus arteriosus,
TOF Tetralogy of Fallot, IAA-a interruption of the aortic arch type a,
IAA-b interruption of the aortic arch type b, COA coarctation of the
aorta, PS pulmonary valve stenosis, AR aortic regurgitation, CAT-II
common arterial trunk type II, DAA double aortic arch
Table 2 Children with Down syndrome and persistent pulmonary
hypertension of the neonate (PPHN) (n=25) and the distribution of a
concomitant congenital heart defect (CHD)
Congenital heart defect (CHD)a N Percent
AVSD 7 28
VSD 6 24
VSD + ASD 3 12
No CHD 9 36
Total 25 100
ASD atrial septal defect, AVSD atrioventricular septal defect, VSD
ventricular septal defect
DS children
registered
n=820
Returned
questionnaires
n=630(76.8%)
Translocation
n=15(2.4%)
Mosaicism
n=10(1.6%)
Trisomy21
n=604(95.9%)
Completed
questionnaires
n=482(79.8%)
CHD+
n=207(43%)
CHD-
n=275(57%)
Other
n=1(0.2%)
Fig. 1 Children with Down syndrome (DS) in the Netherlands born in
the period January 1, 2003 to December 31, 2006 with and without
congenital heart defect (CHD). Asterisk (*) one child had a
combination of trisomy 21 and triple X (0.2%)
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another on day 318 following birth. The data of the
remaining three non-survivors are missing. Among the
neonates with DS who died, 12 children had a CHD (12 out
of 207 CHD children (5.8%)) and four children had no
CHD (4 out of 275 non CHD children, 1.5%). This was a
significant difference in mortality among the children with DS
with and without a CHD, (p=0.008). The causes of death in
the 12 children with DS and a CHD were as follows:
respiratory distress (n=3, all AVSD), neonatal infection (n=2,
AVSD and aortic regurgitation), asphyxia (n=1, AVSD), post
cardiac operation (n=1, AVSD) and necrotizing enterocolitis
(n=1, VSD). In four children, the cause of death was not
documented in the questionnaires (three AVSD and one
PDA). The four children without a CHD died as a result of
asphyxia, respiratory distress and infection, respectively, and
one cause of death was unknown.
Discussion
This is the first large-scall study in the Netherlands
regarding CHDs in children with DS. We found a
prevalence of CHDs of 43%, which is concordant with
the prevalence presented in the literature of 44–58% [3, 4,
7, 8, 14, 15, 17, 20], AVSD (54%) was the most commonly
occurring CHD in children with DS in our study. In our
study, early diagnostic echocardiography was performed.
Secundum ASD and persistent foramen ovale (PFO) were
excluded as a CHD because a small secundum ASD is
sometimes difficult to differentiate from a persistent
foramen ovale, and the study design did not include
follow-up to provide sufficient clarity about ASD versus
PFO [9, 16]. This could have caused an underestimation of
the prevalence of CHD in our study. The early diagnostic
procedure was used to make an early assessment of cardiac
anatomy and in case of a significant defect to perform early
intervention and to prevent pulmonary arterial hypertension
in defects with a left to right shunt.
The inclusion of various cardiac defects and the use of
different terminology in studies with children with DSmade it
difficult to compare these studies with our results. For
instance, Stoll et al. did not report ASD as a CHD as well,
which may explain why PDA is one of the three most
prevalent defects in their study [7, 10, 14, 17]. In our study,
there was no significant difference in the distribution of CHD
according to ethnicity, as the subgroups were too small.
Freeman et al. reported in their study in the United States
of America that black infants with DS had an AVSD more
frequently than whites and that Hispanic infants with DS
had an AVSD less frequently than whites [4]. In Chinese
children with DS and a CHD, VSD was seen in 38% and
AVSD in 25% [7]. AVSDs accounted for only 9% of the
CHDs in Mexican children with DS, while ASD, VSD, and
PDA were most common. This study however began at the
age 13, so the mortality prior to the age of 13 may explain
their distribution of CHDs [3].
Another relevant phenomenon which, to our knowledge,
had not previously been appreciated and as such was not
included in DS guidelines [2, 6] was the significantly
increased incidence of PPHN in neonates with DS (5.2%)
we found in our study. This corresponds with Cua et al. who
estimated the incidence of idiopathic PPHN in neonates with
DS between 1.2% and 6.6%, which is much higher than the
reported overall incidence of 0.1% in the general population
[1]. In our study, only seven children (28%) had an AVSD,
and in these children, we cannot exclude a relationship with
the development of PPHN and nine (36%) children with DS
and PPHN did not have a CHD. In addition Shah et al. found
no serious structural heart defect in 70% of children with DS
and PPHN [13]. PPHN should be distinguished from another
type of pulmonary hypertension, originating from a cardiac
defect that permits left-to-right shunting and requires some
period of time to be clinically detected. The newborn
children with DS, who develop PPHN, are by contrast
symptomatic just after birth [1, 13, 18].
Wren et al. found no clinical signs in the first weeks in
some children with DS, with major cardiac malformations
and associated pulmonary hypertension, even in some who
progressed to irreversible pulmonary vascular disease [21].
A normal neonatal examination in children with DS does
not therefore exclude a serious CHD [11]. This corresponds
with our findings and emphasizes the importance of an early
echocardiography of neonates with DS to detect any CHD and
to determine the possible risk of developing pulmonary
hypertension, as supported by the DS health care guidelines
published by the American Academy of Pediatrics and the
Down Syndrome Medical Interest Group of the United
Kingdom and Ireland [2, 6]. Because of the high incidence
of a significant CHD in children with Down syndrome, the
early recognition of CHD can lead to the optimal manage-
ment of the defect. The surgical correction of significant
defects usually takes place at the age of 2–4 months, though
this happens earlier in certain cases (e.g. TOF) [9, 10].
In our study, basic neonatal characteristics, Apgar scores,
birth weight and gestational age were not different in
children with DS with and without CHD. This is in concords
with Frid et al. who analysed the influence of CHD on these
neonatal issues in 304 neonates with DS and also found no
difference between those with and without CHD [5].
In the past decade, research has shown that neonatal
mortality in DS appears to be becoming less dependent on
CHDs and more often caused by neonatal pathology such
as asphyxia, low birth weight and prematurity, as in the
general population [5, 19]. With regard to mortality, we
should emphasize that with the exception of one child who
died following a cardiac operation, the presence of a CHD
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was not responsible for reported mortality in children with
DS in our recent study.
Our study has several limitations. Because of its
retrospective design, we used data from questionnaires
completed by paediatricians and have no on follow-up data.
Furthermore, there was a sample bias since we could not
use the data of all 820 children with DS who were
registered by the DPSU, 630 (76.8%) questionnaires were
returned and not all questionnaires relating to children with
trisomy 21 had complete data on cardiac status. On the
other hand, the fall out cases were distributed between both
the CHD and non-CHD children with DS.
Though the definition of PPHN was not specifically
defined, diagnosis was based on the clinical assessment and
an echocardiogram performed by the neonatologists and
pediatric cardiologists who answered the questionnaires. It
was impossible to draw a definitive conclusion on the exact
role of the AVSD in the seven children with an AVSD in
relation to the cause of the pulmonary hypertension; neverthe-
less, there were at least 18 other children (3.7% of total) with
PPHN that was not related to a CHD, which is still a high level.
In conclusion, we have demonstrated a 43% prevalence
of CHD in neonates with DS and a significantly increased
and elevated incidence of PPHN in neonates with DS
(5.2%) compared to the general population. Early recog-
nizing the cardiac condition of neonates with DS seems
justified. CHDs had no relationship with neonatal factors
such as gestational age, Apgar score and birth weight of
children with DS. There are no conflicts of interests
There are no conflicts of interests.
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